- Home
- DAWN vs RIGL Comparison
DAWN vs RIGL Comparison
Compare DAWN & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DAWN
- RIGL
- Stock Information
- Founded
- DAWN 2018
- RIGL 1996
- Country
- DAWN United States
- RIGL United States
- Employees
- DAWN N/A
- RIGL N/A
- Industry
- DAWN Biotechnology: Pharmaceutical Preparations
- RIGL Biotechnology: Pharmaceutical Preparations
- Sector
- DAWN Health Care
- RIGL Health Care
- Exchange
- DAWN Nasdaq
- RIGL Nasdaq
- Market Cap
- DAWN 624.8M
- RIGL 537.6M
- IPO Year
- DAWN 2021
- RIGL 2000
- Fundamental
- Price
- DAWN $9.39
- RIGL $51.48
- Analyst Decision
- DAWN Strong Buy
- RIGL Strong Buy
- Analyst Count
- DAWN 9
- RIGL 5
- Target Price
- DAWN $26.56
- RIGL $43.20
- AVG Volume (30 Days)
- DAWN 3.4M
- RIGL 774.9K
- Earning Date
- DAWN 11-04-2025
- RIGL 11-04-2025
- Dividend Yield
- DAWN N/A
- RIGL N/A
- EPS Growth
- DAWN N/A
- RIGL 2698.26
- EPS
- DAWN N/A
- RIGL 6.20
- Revenue
- DAWN $133,672,000.00
- RIGL $282,076,000.00
- Revenue This Year
- DAWN $12.88
- RIGL $59.93
- Revenue Next Year
- DAWN $48.27
- RIGL N/A
- P/E Ratio
- DAWN N/A
- RIGL $8.22
- Revenue Growth
- DAWN 31.11
- RIGL 79.13
- 52 Week Low
- DAWN $5.64
- RIGL $14.63
- 52 Week High
- DAWN $14.46
- RIGL $51.73
- Technical
- Relative Strength Index (RSI)
- DAWN 60.96
- RIGL 73.90
- Support Level
- DAWN $8.16
- RIGL $34.00
- Resistance Level
- DAWN $9.77
- RIGL $50.23
- Average True Range (ATR)
- DAWN 0.70
- RIGL 3.08
- MACD
- DAWN -0.02
- RIGL 1.13
- Stochastic Oscillator
- DAWN 45.44
- RIGL 96.45
About DAWN Day One Biopharmaceuticals Inc.
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, and kinase inhibitor.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.